series-c-plus
Stage
4
Investors
About
Acticor Biotech is a clinical-stage biotechnology company developing glenzocimab, a novel therapeutic agent for the treatment of acute ischemic stroke. Its mission is to improve patient outcomes for this condition.
Explore Acticor Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.